免疫抑制劑在臨床上多用于防治免疫異常所致的疾病，如抗器官移植排斥反應(yīng)和自身免疫性疾病。然而，免疫抑制劑在臨床應(yīng)用中具有明顯的肝臟不良反應(yīng)，臨床上多采用高效低毒的新型免疫抑制劑、免疫抑制劑間聯(lián)合用藥和聯(lián)合保肝藥等方式，以減少其肝臟不良反應(yīng)。對糖皮質(zhì)激素、環(huán)孢素、他克莫司、硫唑嘌呤、環(huán)磷酰胺、雷公藤多苷和來氟米特等常用的免疫抑制劑所致肝損傷的研究進(jìn)展進(jìn)行綜述，以期為免疫抑制劑在臨床上的安全用藥提供參考依據(jù)。

Immunosuppressant is widely used to prevent and cure diseases caused by immune abnormalities, such as organ transplant rejection and autoimmune diseases. However, immunosuppressive agents have obvious hepatic adverse reactions in clinical application. In clinical practice, new immunosuppressants with high efficiency and low toxicity, combined use of immunosuppressants and combined hepatoprotective drugs are often used to reduce liver adverse reactions. In this paper, the research progress of liver injury induced by immunosuppressants such as glucocorticoid, cyclosporine, tacrolimus, azathioprine, cyclophosphamide, tripterygium glycosides and lefluride was reviewed, which provided reference for the safe use of immunosuppressants in clinical practice.

R979.5，R969.3

國家自然科學(xué)基金面上資助項(xiàng)目(82074114,81973562)